Skip to main content

Table 5 Endometrial cancer mortality and tamoxifen use, by morphology

From: Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries

  All morphological types Morphologya
      Endometrioid Non-endometrioidb
  d n HRc 95% CI d n HRd 95% CI d n HRd 95% CI
Tamoxifen use
   Not used 86 737 1.00 baseline 57 651 1.00 baseline 27 80 1.00 baseline
   Used 191 1138 1.17 0.89, 1.55 105 929 1.01 0.72, 1.43 79 190 1.19 0.74, 1.89
  P-het (1 d.f.) = 0.26 P-interaction (1 d.f.) = 0.57
Duration of tamoxifen use
   Not used 86 737 1.00 baseline 57 651 1.00 baseline 27 80 1.00 baseline
   Used, < 2 years 29 313 0.71 0.46, 1.09 20 272 0.77 0.46, 1.29 8 40 0.50 0.23, 1.12
   2 - < 5 years 61 397 1.18 0.84, 1.67 27 326 0.82 0.51, 1.32 30 62 1.64 0.94, 2.86
   5 or more years 86 365 1.59 1.13, 2.25 49 285 1.43 0.94, 2.19 35 73 1.56 0.91, 2.69
   Used, duration unknown 15 63 2.45 1.38, 4.36 9 46 3.14 1.50, 6.57 6 15 1.29 0.51, 3.26
  P-het (4 d.f.) = 0.0002 P-trend interaction (1 d.f.) = 0.36
  P-trend (1 d.f.) = 0.0055 P-trend (1 d.f.) = 0.0023 P-trend (1 d.f.) = 0.22
Cumulative tamoxifen dose (mg)e
   Not used 86 737 1.00 baseline 57 651 1.00 baseline 27 80 1.00 baseline
   Used, < 7500 16 132 0.90 0.52, 1.55 12 114 1.06 0.57, 2.00 4 18 0.57 0.20, 1.65
   7500 to < 15,000 15 159 0.72 0.41, 1.26 9 138 0.63 0.31, 1.29 5 20 0.83 0.31, 2.18
   15,000 to < 30,000 32 239 1.06 0.70, 1.61 15 199 0.84 0.47, 1.51 15 35 1.38 0.72, 2.64
   30,000 to < 60,000 56 294 1.40 0.97, 2.02 23 230 0.91 0.55, 1.51 31 59 1.64 0.94, 2.87
   ≥ 60,000 52 230 1.40 0.95, 2.05 32 185 1.29 0.81, 2.07 18 41 1.26 0.68, 2.36
   Used, amount unknown 20 84 2.13 1.26, 3.58 14 63 2.86 1.54, 5.33 6 17 1.11 0.44, 2.81
  P-het (6 d.f.) = 0.022 P-trend interaction (1 d.f.) = 0.89
  P-trend (1 d.f.) = 0.10 P-trend (1 d.f.) = 0.38 P-trend (1 d.f.) = 0.36
Daily tamoxifen dose (mg/day)
   Not used 86 737 1.00 baseline 57 651 1.00 baseline 27 80 1.00 baseline
   < 25 mg/dayf 115 738 1.10 0.81, 1.50 63 610 0.97 0.66, 1.43 49 119 1.32 0.79, 2.20
   ≥ 25 mg/dayg 62 343 1.25 0.88, 1.76 31 277 0.94 0.59, 1.48 27 59 1.11 0.64, 1.93
   Used, dose unknown 14 57 1.74 0.96, 3.15 11 42 2.65 1.35, 5.20 3 12 0.72 0.21, 2.50
  P-het (3 d.f.) = 0.28 P-trend interaction (1 d.f.) = 0.90
  P-trend (1 d.f.) = 0.86 P-trend (1 d.f.) = 0.68 P-trend (1 d.f.) = 0.60
Time since last use (based on date of diagnosis of endometrial cancer)
   Not used 86 737 1.00 baseline 57 651 1.00 baseline 27 80 1.00 baseline
   Still on/≤ 3 months 107 764 0.92 0.68, 1.26 62 649 0.82 0.56, 1.21 42 108 1.11 0.66, 1.88
   3 months to < 1 year 14 87 1.12 0.63, 1.99 9 70 1.27 0.62, 2.62 4 13 0.64 0.22, 1.85
   1 year to < 3 years 20 100 1.62 0.99, 2.67 7 73 0.90 0.41, 1.98 12 24 1.64 0.82, 3.30
   3 years to < 5 years 13 53 1.91 1.05, 3.46 5 35 1.39 0.55, 3.50 6 15 1.82 0.73, 4.55
   5 or more years 22 72 2.22 1.36, 3.61 13 56 2.11 1.13, 3.94 9 16 1.52 0.68, 3.38
   Used, time unknown 15 62 2.11 1.19, 3.72 9 46 3.08 1.49, 6.38 6 14 1.23 0.49, 3.11
  P-het (6 d.f.) = 0.0007 P-trend interaction (1 d.f.) = 0.52
  P-trend (1 d.f.) = 0.012 P-trend (1 d.f.) = 0.0033 P-trend (1 d.f.) = 0.20
Interval between tumors           
   3 - 11 months 9 116 0.83 0.40, 1.69 8 102 1.08 0.49, 2.38 1 13 0.19 0.02, 1.43
   1 - 2 years 44 453 1.00 baseline 29 400 1.00 baseline 14 48 1.00 baseline
   3 - 4 years 47 357 1.33 0.88, 2.01 22 305 1.02 0.59, 1.79 22 48 1.16 0.58, 2.33
   5 - 9 years 110 635 1.62 1.13, 2.32 56 508 1.41 0.89, 2.23 52 117 1.31 0.71, 2.42
   10 - 29 years 67 314 2.06 1.38, 3.08 47 265 2.18 1.35, 3.53 17 44 1.01 0.47, 2.16
  P-het (4 d.f.) = 0.0017 P-interaction (1 d.f.) = 0.13
  P-trend (1 d.f.) = 0.0048 P-trend (1 d.f.) = 0.0003 P-trend (1 d.f.) = 0.49
  1. aExcludes those (9 endometrial deaths among 25 patients) where morphology was missing; bSerous and clear cell, carcinosarcoma, sarcoma, excludes those where morphology unknown; cAdjusted for time since diagnosis of endometrial cancer, study, calendar period, and attained age; dAdjusted for time since diagnosis of endometrial cancer, study, calendar period, attained age, and FIGO stage; eTrend evaluated on log10 transformed cumulative dose;
  2. fMostly 20 mg/day; gMostly 40 mg/day. CI, confidence interval; d, number of deaths attributed to endometrial cancer; HR, hazard ratio; n, number of patients.